Ardelyx (ARDX) investor relations material

Strategic priorities and business overview

• Focused on unmet patient needs with two commercialized products: IBSRELA for IBS-C and XPHOZAH for dialysis patients with hyperphosphatemia.

• 2026 strategic priorities: increase IBSRELA demand, maintain XPHOZAH momentum, advance pipeline, and sustain strong financial performance.

• Combined revenue for both products expected to exceed $500 million in 2026, with IBSRELA contributing over $400 million.

IBSRELA growth drivers and market strategy

• IBSRELA projected to generate $410–$430 million in 2026, driven by expanded sales force and targeted physician engagement.

• Sales force doubled in late 2024, with further expansion to 144 reps in July 2026 to optimize coverage of 14,000 HCPs.

• Specialty pharmacy channel now accounts for 30–33% of scripts, improving fulfillment rates and patient adherence.

• Patient engagement initiatives, including digital and social campaigns, aim to increase awareness and drive office visits.

• Long-term guidance targets $1 billion in IBSRELA revenue by 2029, requiring a 38% CAGR from current levels.

XPHOZAH performance and outlook

• XPHOZAH guided to $110–$120 million in 2026, with 19% paid prescription growth and 32% total prescription growth in Q1.

• Long-term revenue target of $750 million before loss of exclusivity, supported by ongoing growth in paid prescriptions.

• Market disruption from TDAPA period and potential new entrants acknowledged, but product positioned for continued demand.

• Patient assistance programs and broad payer access support continued uptake.